Insider Buying: Septerna, Inc. (NASDAQ:SEPN) CFO Buys 10,500 Shares of Stock

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie bought 10,500 shares of the stock in a transaction on Wednesday, February 19th. The stock was purchased at an average price of $5.51 per share, with a total value of $57,855.00. Following the completion of the acquisition, the chief financial officer now directly owns 10,500 shares in the company, valued at approximately $57,855. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Septerna Price Performance

Shares of NASDAQ SEPN opened at $5.80 on Friday. Septerna, Inc. has a 1-year low of $4.17 and a 1-year high of $28.99. The stock’s fifty day moving average is $17.78.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on SEPN shares. JPMorgan Chase & Co. started coverage on Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price for the company. TD Cowen started coverage on Septerna in a report on Tuesday, November 19th. They issued a “buy” rating for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $50.00 target price on shares of Septerna in a report on Tuesday, February 11th. Finally, Wells Fargo & Company cut Septerna from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $43.00 to $14.00 in a report on Tuesday, February 18th.

Institutional Investors Weigh In On Septerna

Hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC purchased a new stake in shares of Septerna during the 4th quarter worth $25,000. New York State Common Retirement Fund purchased a new stake in shares of Septerna during the 4th quarter worth $32,000. Legal & General Group Plc purchased a new stake in shares of Septerna during the 4th quarter worth $42,000. Summit Investment Advisors Inc. purchased a new stake in shares of Septerna during the 4th quarter worth $45,000. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Septerna during the 4th quarter worth $52,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.